Form 4: OptimizeRx Corp Executive Doug Besch Reports Stock Transactions
SEC Form 4 Filing
Doug Besch, Chief Product Officer of OptimizeRx Corp, reports the vesting and subsequent disposal of shares to cover tax obligations.
Summary
- On October 3, 2024, Doug Besch, Chief Product Officer of OptimizeRx Corp, reported transactions involving common stock and restricted stock units.
- 3,324 restricted stock units vested and converted into common stock on a one-for-one basis.
- 976 shares were disposed of to satisfy tax withholding obligations at a price of $7.83 per share.
- Following these transactions, Besch directly owns 10,196 shares of common stock and 3,325 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they involve the vesting of previously granted equity compensation and a small disposal of shares to cover taxes.
Key Dates
| Date | Description |
|---|---|
| 10/03/2023 | First anniversary of the grant date for restricted stock units. |
| 10/03/2024 | Date of the reported transactions: vesting of restricted stock units and disposal of shares for tax obligations. |
| 10/07/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.